Clinical Trials Logo

Disease Progression clinical trials

View clinical trials related to Disease Progression.

Filter by:
  • Completed  
  • Page 1 ·  Next »

NCT ID: NCT06235853 Completed - Bladder Cancer Clinical Trials

Biomarkers of Recurrence and Progression in Non-muscle Invasive Bladder Cancer

Start date: January 1, 2020
Phase:
Study type: Observational

Bladder cancer (BC) is one of the most common type of cancer globally. Due to its high incidence rate, high risk of recurrence and progression, and frequent cystoscopy surveillance, BC contributes to major healthcare costs across the world. The goal of this prospective study was to evaluate the prognostic value of novel non-muscle invasive bladder cancer (NMIBC) biomarkers for predicting disease recurrence or progression after radical transurethral resection of bladder tumour (TURBT). The data obtained from this study may help physicians identify patients who are at greater risk of NMIBC recurrence or progression and require close supervision.

NCT ID: NCT06135116 Completed - Periodontitis Clinical Trials

Regulatory T Cell With Related Interleukins in Periodontal Disease Progression

Start date: November 1, 2023
Phase:
Study type: Observational

T Regulatory cells which suppressor subset of T cells and related cytokines remain in blood and infiltrates into the tissue under need. The role of Treg and related cytokines in succession of periodontal inflammation is recently a subject of research interest. Chronic gingivitis and periodontitis being chronic inflammatory diseases can upregulate various cytokines in the systemic circulation and gingival crevicular fluid. This study aimed to compare levels of Tregs with Interleukin-21, 22, 33, 35 and vitamin D-binding protein in blood and GCF of periodontally healthy persons, chronic gingivitis patients, and severe chronic periodontitis patients.

NCT ID: NCT06118684 Completed - COPD Clinical Trials

Clinical Trial to Assess Effect of Verapamil on Systemic Exposure of EP395 and Effect of EP395 on Systemic Exposure of Midazolam and Digoxin

Start date: October 23, 2023
Phase: Phase 1
Study type: Interventional

The aim of this trial is to assess the potential key drug-drug interactions with EP395 in the clinical setting.

NCT ID: NCT06042400 Completed - Anxiety Clinical Trials

Trial of Written Exposure for Metastatic Cancer Patients (EASE)

Start date: April 18, 2022
Phase: N/A
Study type: Interventional

In the face of imminent loss, many adults with metastatic cancer report a range of mental health challenges, including cancer-related trauma symptoms, fear of cancer progression and dying/death, anxiety, depression, and hopelessness, as well as physical symptoms such as fatigue and pain. Cancer patients may report feeling upset or haunted by imagined scenarios in a way that causes them distress and lowers their quality of life. This study aims to look at the acceptability and feasability of a writing-based intervention for adults with late-stage or recurrent cancer, or actively treated blood cancer. The EASE study uses a writing-based approach to address an individual's worst-case scenario about cancer because previous studies have shown that similar approaches have shown promise in reducing fear in early-stage cancer survivors and among adults with PTSD (posttraumatic stress disorder). The EASE study represents a novel adaptation of this foundational work on written exposure therapy (WET) to address worst-case scenarios among adults with late stage cancers. The EASE study will include 5 weekly one-on-one online video sessions with a trained therapist where participants will be coached through writing exercises based on a worst-case scenario related to their cancer experience.

NCT ID: NCT05991778 Completed - Septic Shock Clinical Trials

Bioelectrical Impedance in Monitoring Hyperhydration and Polyneuromyopathy in Critically Ill Patients

Start date: March 1, 2021
Phase:
Study type: Observational

This prospective, blinded observational clinical study was aimed to determine the effect of hyperhydration and muscle loss measured by Bioelectrical impedance vector analysis (BIVA) on mortality. The aim was to compare hydratation parameters measured by BIVA: OHY, Extracellular Water (ECW) / Total Body Wate (TBW) and quadrant, vector length, phase angle (PA) with cumulative fluid balance (CFB) recording (input-output) in their ability in predicting mortality as the abilities of the prognostic markers PA (BIVA), Acute Physiology and Chronic Health Evaluation II (APACHE II - score) and presepsin (serum Cluster of Differentiation (CD) 14-ST). The investigators also compared BIVA nutritional indicators (SMM, fat) with BMI and laboratory parameters (albumin, prealbumin and C-reactive protein (CRP) inflammation parameters) in the prediction of mortality. An important goal was to evaluate the usability of the BIVA method in critically ill patients on extracorporeal circulation, to compare the impedance data of the extracorporeal membrane oxygenation (ECMO) and non-ECMO groups.

NCT ID: NCT05934461 Completed - Clinical trials for The Primary Study Metric is Progression-free Survival (PFS)

A Retrospective Study of Radiotherapy Combined With EGFR-TKI for Stage III EGFR Mutant Lung Cancer

Start date: December 1, 2014
Phase:
Study type: Observational

Objective: To investigate the efficacy and safety of radiotherapy combined with EGFR-KI in the treatment of stage III EGFR mutant lung cancer. Methods: Stage III EGFR mutant lung cancer cases who underwent radiotherapy combined with EGFR-TKI from December 2014 to December 2022 at the People's Hospital of Laibin, the First People's Hospital of Yulin, the Affiliated Hospital of Guilin Medical College, and the Park East Hospital of Guangxi Medical University Kaiyuan were collected, and the primary index of the study was progression-free survival (PFS), and the secondary indexes were objective remission rate, overall survival, recurrence pattern, and adverse events. Survival analysis was performed using the Kaplan-Meier method with Log rank test for univariate analysis and Cox proportional risk model for multifactorial analysis of prognosis.

NCT ID: NCT05776654 Completed - Clinical trials for Chronic Obstructive Pulmonary Disease

Wearable Devices in the Recovery Phase of Acute Exacerbations of COPD (AECOPDs)

Start date: February 16, 2023
Phase:
Study type: Observational

The purpose the study is to successfully characterize the recovery phase of acute exacerbations of COPD in the outpatient setting using remotely captured physiologic data from wearable devices, to compare this with patient self-reported symptom data, to determine which physiologic variable(s) best correspond with AECOPD recovery, and to further document the feasibility, data quantity, data quality, and COPD outpatient usability experience with wearable devices.

NCT ID: NCT05716386 Completed - Blood Pressure Clinical Trials

Effect of Low Salt and Ckd Progression

Start date: February 28, 2023
Phase: N/A
Study type: Interventional

Whether an intensive short-term dietary sodium restricted intervention will have beneficial effects on the glomerular filtration rate (GFR) and on the susceptibility to develop proteinuria, both measures of kidney function will be the objective of this study

NCT ID: NCT05700240 Completed - Myopia Progression Clinical Trials

Effect of Orthokeratology on Myopia Progression in French Children

Start date: November 2, 2019
Phase:
Study type: Observational

To evaluate and to compare the effect of orthokeratology (OK) on axial elongation in French myopic children.

NCT ID: NCT05699720 Completed - Magnesium Sulfate Clinical Trials

Acute Exacerbation of COPD and Nebulized Magnesium Sulphate

Start date: January 1, 2019
Phase: N/A
Study type: Interventional

This study is designed to determine the effect of Nebulized Magnesium Sulphate as an add-on therapy with conventional treatment on In-hospital outcome in patients having acute exacerbation of COPD.